One in five privately insured adults denied doctor-ordered care, new surveys find

The fine print in your health insurance policy might as well be a gag line, except nobody’s laughing. And the punchline lands square on the backs of paying customers who discover too late that their coverage is a mirage.

Two major national surveys, released within days of each other, deliver the same grim diagnosis: America’s private health insurance system is systematically refusing to pay for the very care it promises to cover.

One in five working-age adults with private insurance—21 percent—report that they or a family member had a claim denied by their insurance company for medical care their own doctor recommended, according to a Commonwealth Fund survey released June 4. The denial came either before or after the care was provided. The survey analyzed responses from nearly 4,600 privately insured adults.

Seven out of ten patients were forced to delay needed medical treatments due to insurer policies that prioritize profit over people, while one in five were initially denied coverage for a claim prescribed by their doctor.

That is not a niche problem. That is a public health catastrophe wearing a necktie and sitting in a C-suite.

A separate analysis from IQVIA, a health care consulting firm, found that 70 percent of commercially insured patients were initially denied coverage for at least one newly prescribed brand-name medicine in 2024.

Seven out of 10 patients walked to the pharmacy counter and were turned away. Not because the drug didn’t work. Not because the doctor was wrong. Because an insurer said no.

And here is where the story turns from infuriating to indefensible: Nearly a quarter of those patients—24 percent—never got approval at all, even after a full year of appeals, phone calls, and paperwork. Their recommended treatment simply evaporated into the bureaucracy.

The Commonwealth Fund survey, conducted in 2023 and released this month, found that 41 percent of people who experienced a denial said it delayed their medical care. Twenty-eight percent said a health issue actually worsened because of it. That means real people with real conditions—cancer, diabetes, heart disease, chronic pain—got sicker while waiting for an insurance clerk to decide whether their doctor knew what he was talking about.

Only about half of those denied coverage bothered to appeal. The others cited confusion about their rights, uncertainty about whether an appeal would matter, and no clear idea of whom to contact. The system is designed to exhaust you before it ever examines you.

The IQVIA data, which tracks claim-level denials across commercial insurance plans, shows initial rejection rates for new brand-name prescriptions climbed 13 percentage points between 2021 and 2025. That is not a blip. That is a trend line with teeth.

Most commercial patients start only one new brand-name medicine per year, the study found, meaning the denial is personal. It is not a statistical artifact. It is a door slamming shut.

Among patients who eventually won approval after an initial denial, 44 percent were granted the same day—which raises a pointed question: If the denial could be resolved in a matter of hours, why was it issued at all? The average approval time stretched to 16 days in 2024, up from 12 days in 2021. One in 10 patients waited more than a month.

That is not managed care. That is managed delay.

The Commonwealth Fund survey, which included more than 6,100 working-age adults, also found that 43 percent of people with employer-sponsored insurance said it was difficult to afford their health care. Thirty percent were carrying medical debt. Among those with debt, more than a third delayed or skipped needed care because of the bills.

Medical debt is not an accident. It is a business model.

The IQVIA analysis was sponsored by the Pharmaceutical Research and Manufacturers of America, an industry trade group with its own axe to grind. But the numbers come from claims data, not opinion polls. And they align almost exactly with the Commonwealth Fund’s findings from patient surveys.

Two different methods. Two different sources. One conclusion.

Insurance companies defend these denials as necessary cost controls, tools to prevent unnecessary or ineffective treatments. But when seven out of 10 initial claims for a doctor-prescribed brand-name drug are rejected, and nearly half of those rejections are overturned quickly on appeal, the argument that these decisions are rooted in medical necessity collapses under its own weight.

What remains is a system that defaults to no. A system that bets most patients will simply give up. And a growing body of evidence that the bet is paying off—not for patients, but for the house.